What Squalene Is Actually Proven to Do — and Why Most of It Comes From the Wrong Source

Squalene has two separate identities worth separating: it's a human skin lipid the body already makes (present naturally in sebum, roughly 10-12% of it, which is a large part of why topical squalene and squalane are so well tolerated across skin types), and it's a plant-derived compound Arceli extracts from Amaranthus seed rather than the shark-liver source that has historically supplied much of the cosmetic market.

The dermal evidence. A study on human dermal fibroblasts exposed to UVA radiation found that squalane (squalene's stable, fully saturated, hydrogenated form) at concentrations of just 0.005–0.015% counteracted UVA-induced oxidative stress and the associated inhibition of collagen biosynthesis. The same study found squalane suppressed the UVA-induced rise in NF-κB and COX-2, two of the principal signaling molecules that drive skin inflammation after UV exposure — meaning the effect is anti-inflammatory and collagen-protective at the cellular level, not just a surface-level moisturizing claim. Separately, published clinical research on topical squalane application reports measurable increases in skin moisture alongside reduced trans-epidermal water loss (TEWL) — the rate at which skin loses water through a compromised barrier — consistent with squalane's role in replenishing depleted lipids in the stratum corneum, the skin's outermost barrier layer.

Squalane's chemical stability is itself part of the clinical relevance. Squalene, in its natural unsaturated form, oxidizes readily on skin and on the shelf; squalane, the hydrogenated version formulators actually use, is fully saturated and highly resistant to that oxidative degradation. That stability is what preserves the moisturizing and antioxidant activity described above over a product's real shelf life, rather than only in a freshly-prepared lab sample.

Why Amaranthus, specifically. Most commercial squalene has historically come from shark liver oil — a supply chain with real ethical sourcing concerns and increasing regulatory scrutiny — or from olive oil, where concentrations are low enough that extraction is inefficient at scale. Amaranthus seed oil is a genuine plant-based alternative with real, published yield data behind it. Amaranth seeds are roughly 4–8% oil by seed mass, and that oil itself has been reported at 6–8% squalene content by published supercritical CO2 (SCFE) extraction studies on Amaranthus hypochondriacus and cruentus seed.

Critically, the extraction parameters matter as much as the source: one study found that while the highest overall oil yield (64% of seed mass) came from higher pressure, lower temperature, and longer extraction time, the highest squalene concentration in that oil (60%) instead required lower pressure, higher temperature, and a shorter extraction window — meaning "extracting Amaranthus oil" and "extracting Amaranthus oil optimized for squalene concentration" are two different processes with different optimal conditions, and getting it wrong measurably dilutes the yield.

This is the same extraction method — supercritical CO2 — that Arceli already runs at its Dehradun facility across its full catalog. SquaActive™ isn't sourced through a separate, bolted-on process; it's the same 300L SCFE platform tuned to the extraction conditions that concentrate squalene specifically, applied to a different feedstock than the rest of the ArcoPure™ line.

What this means in practice. A squalene ingredient's real value proposition is purity, source traceability, and consistency — not the base molecule itself, since squalene is chemically identical regardless of source. The differentiation that actually matters to a formulator is traceable, ethical, plant-based sourcing instead of animal-derived material, and the batch-to-batch consistency of a CO2-extracted, standardized oil against the variable purity typical of cheaper cold-pressed or solvent-extracted alternatives, where squalene content and oxidative state can shift meaningfully between lots.

Squalene has been used as a vaccine-adjuvant component for decades, most commonly sourced from shark liver oil. Supply constraints, sustainability concerns and batch-to-batch variability in marine-sourced squalene have pushed formulators to look for plant-based alternatives that can match the same purity bar.

Amaranthus-derived squalene, standardized to 99% HPLC purity, is one such alternative. Because Amaranthus is a cultivated crop rather than a wild-caught marine byproduct, supply is more predictable and traceable — a meaningful advantage for pharmaceutical procurement teams that need to plan multi-year supply agreements.

It's worth being precise about the claim here: a standardized, high-purity plant-based squalene is a credible adjuvant component supplier story, not a vaccine efficacy claim. Any formulator evaluating this substitution should validate performance in their own adjuvant system before making a switch.